Dimethyl Sulfoxide USP, PhEur in Approved Pharmaceutical Products and Medical Devices - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Dimethyl Sulfoxide USP, PhEur in Approved Pharmaceutical Products and Medical Devices
The authors survey the approved applications of dimethyl sulfoxide USP, PhEur across the healthcare industry and consider the suitability of DMSO from a regulatory and formulation compatibility standpoint.


Pharmaceutical Technology


Formulation aspects


Table I: Basic physical properties of dimethyl sulfoxide.
Solubility of excipients and API compounds. Dimethyl sulfoxide USP, PhEur is chemically compatible with many pharmaceutical excipients and APIs. A database providing solubility data for more than 100 drug compounds and 30 excipients is available on-line (15), dimethyl sulfoxide USP is referenced in The Handbook of Pharmaceutical Excipients (16). Some basic physical properties of DMSO are listed in Table I.


Table II: Common solubilizing excipient solubilities in dimethyl sulfoxide (solvent).*
DMSO is completely miscible with water, ethanol, propylene carbonate, and propylene glycol. It is practically insoluble–insoluble in many lipophilic ingredients (e.g., light mineral oil USP, soybean oil NF). Table II provides an overview of solubility data for dimethyl sulfoxide USP, with common solubilizing excipients.

It is worthwhile to note that water has a dramatic effect on the properties of dimethyl sulfoxide USP, PhEur (17). Although this may be a useful means to lower the solvent strength of DMSO in limited applications, water contamination in DMSO products may affect formulation stability in a negative sense if formulation components have a low degree of water solubility. Mixtures that are high in water content take on the general solvent properties of water. DMSO is fully hydrated at 67 wt% strength in water (10).


Table III: Common viscosity modifying excipient solubilities in dimethyl sulfoxide.*
Viscosity and rheology modification. The viscosity of DMSO formulations may be modified using additives that work well in water. Some pharmaceutically acceptable materials that may be used for this purpose include hydroxypropyl cellulose (Klucel, Hercules Aqualon Corp.), hypromellose USP (Methocel E3 Premium LV, Dow Chemical), carbomers (Carbopol, Noveon Corp.), and methylcellulose USP. Although such materials have low solubility levels in DMSO (see Table III), very low loading levels are capable of producing high-viscosity gels.

A standard procedure for producing a thickened solution (~10,000 cPs, depending upon the product used) from a DMSO base follows: Dimethyl sulfoxide (100 g) is combined with triethanolamine (0.5 g) and is stirred mechanically. Klucel LF (0.5 g) is sifted into the mixture slowly; hasty addition of Klucel can result in its aggregation into clumps which are difficult to disperse. It can be helpful to sift the Klucel into the mixture by passing it through a screen. The mixture is stirred at room temperature for 30 min., at which point no solids are seen to the naked eye.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here